CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Cetuximab +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00857246
NCT00857246Phase 2Completed
CompareCT.gov

Neoadjuvant Therapy of Gastric Cancer With Irinotecan, Cisplatin and Cetuximab Followed by Surgical Resection and Adjuvant Chemoradiation

NYU Langone Health·interventional·Posted Mar 6, 2009·Updated Dec 7, 2015

In Brief

A Phase 2 clinical trial evaluating Cetuximab, Irinotecan, and 4 other interventions for Gastric Cancer and Stomach Cancer. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This study intends to evaluate the feasibility and treatment efficacy of adding an antibody blocking the epidermal growth factor (EGF) pathway to a neoadjuvant approach with proven efficacy developed at New York University.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer, Stomach Cancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb, Eli Lilly and Company

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 6, 2009
Enrollment StartJul 1, 2005
Primary CompletionSep 1, 2011
Study CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 17.3 years ago

Interventions

Cetuximabdrug

Irinotecandrug

Cisplatindrug

Surgeryprocedure

5-FUdrug

Radiationradiation